Advanced search
Publication Cover
Clinical Ophthalmology Volume 14, 2020 - Issue
Submit an article Journal homepage
204
Views
4
CrossRef citations to date
0
Altmetric
Original Research

Symptom Relief Following a Single Dose of Propylene Glycol-Hydroxypropyl Guar Nanoemulsion in Patients with Dry Eye Disease: A Phase IV, Multicenter Trial

Steven Silverstein1 Silverstein Eye Centers, Kansas City, MO64133, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-8243-2485View further author information
ORCID Icon,
Elizabeth Yeu2 Virginia Eye Consultants, Norfolk, VA23502, USAORCID Iconhttps://orcid.org/0000-0002-3453-3062View further author information
ORCID Icon,
Joseph Tauber3 Tauber Eye Center, Kansas City, MO64155, USAORCID Iconhttps://orcid.org/0000-0001-5365-8795View further author information
ORCID Icon,
Michel Guillon4 Ocular Technology Group International, LondonSW1E 6AU, UKORCID Iconhttps://orcid.org/0000-0002-1929-8690View further author information
ORCID Icon,
Lyndon Jones5 Centre for Ocular Research & Education (CORE), School of Optometry and Vision Science, Waterloo, ONNL2 3G1, Canada;6 Centre for Eye and Vision Research Limited (CEVR), Hong KongORCID Iconhttps://orcid.org/0000-0002-7409-7349View further author information
ORCID Icon,
David Galarreta7 Hospital Clinico Universitario de Valladolid, Valladolid Castilla y Leon47011, SpainORCID Iconhttps://orcid.org/0000-0001-5649-6971View further author information
ORCID Icon,
Sruthi Srinivasan8 Alcon Research, LLC, Johns Creek, GA, USAORCID Iconhttps://orcid.org/0000-0001-9697-1343View further author information
ORCID Icon &
Venkiteshwar Manoj8 Alcon Research, LLC, Johns Creek, GA, USAView further author information
 show all
Pages 3167-3177 | Published online: 09 Oct 2020

References

  • Craig JP, Nichols KK, Akpek EK, et al. TFOS DEWS II definition and classification report. Ocul Surf. 2017;15(3):276–283. doi:10.1016/j.jtos.2017.05.008
  • Friedman NJ. Impact of dry eye disease and treatment on quality of life. Curr Opin Ophthalmol. 2010;21(4):310–316. doi:10.1097/ICU.0b013e32833a8c15
  • Stapleton F, Alves M, Bunya VY, et al. TFOS DEWS II epidemiology report. Ocul Surf. 2017;15(3):334–365. doi:10.1016/j.jtos.2017.05.003
  • Jones L, Downie LE, Korb D, et al. TFOS DEWS II management and therapy report. Ocul Surf. 2017;15(3):575–628. doi:10.1016/j.jtos.2017.05.006
  • Willcox MDP, Argueso P, Georgiev GA, et al. TFOS DEWS II tear film report. Ocul Surf. 2017;15(3):366–403. doi:10.1016/j.jtos.2017.03.006
  • Patra JK, Das G, Fraceto LF, et al. Nano based drug delivery systems: recent developments and future prospects. J Nanobiotechnology. 2018;16(1):71. doi:10.1186/s12951-018-0392-8
  • Benelli U. Systane lubricant eye drops in the management of ocular dryness. Clin Ophthalmol. 2011;5:783–790. doi:10.2147/OPTH.S13773
  • Rangarajan R, Ketelson H. Preclinical evaluation of a new hydroxypropyl-guar phospholipid nanoemulsion-based artificial tear formulation in models of corneal epithelium. J Ocul Pharmacol Ther. 2019;35(1):32–37. doi:10.1089/jop.2018.0031
  • Korb DR, Greiner JV, Glonek T. The effects of anionic and zwitterionic phospholipids on the tear film lipid layer. Adv Exp Med Biol. 2002;506(Pt A):495–499.
  • Yeu E, Silverstein S, Guillon M, et al. Efficacy and safety of phospholipid nanoemulsion-based ocular lubricant for the management of various subtypes of dry eye disease: a phase IV, multicenter trial. Clinical Ophthalmol. 2020.
  • Tauber J, Karpecki P, Latkany R, et al. Lifitegrast ophthalmic solution 5.0% versus placebo for treatment of dry eye disease: results of the randomized Phase III OPUS-2 study. Ophthalmology. 2015;122(12):2423–2431. doi:10.1016/j.ophtha.2015.08.001
  • Nichols KK, Holland E, Toyos MM, et al. Ocular comfort assessment of lifitegrast ophthalmic solution 5.0% in OPUS-3, a phase III randomized controlled trial. Clin Ophthalmol. 2018;12:263–270. doi:10.2147/OPTH.S152841
  • Jerkins G, Greiner V, Tong L, et al. A comparison of efficacy and safety of two lipid-based lubricant eye drops for the management of evaporative dry eye disease. Clin Ophthalmol. 2020;14:1665–1673. doi:10.2147/OPTH.S256351
  • Systane Complete. Available from: https://systane.myalcon.com/eye-care/systane/products/systane-complete/. Accessed December 26, 2019.
  • Aguilar AJ, Marquez MI, Albera PA, Tredicce JL, Berra A. Effects of systane((R)) balance on noninvasive tear film break-up time in patients with lipid-deficient dry eye. Clin Ophthalmol. 2014;8:2365–2372. doi:10.2147/OPTH.S70623
  • Gifford P, Evans BJ, Morris J. A clinical evaluation of systane. Cont Lens Anterior Eye. 2006;29(1):31–40. doi:10.1016/j.clae.2005.12.003
  • Johnson ME, Murphy PJ, Boulton M. Effectiveness of sodium hyaluronate eyedrops in the treatment of dry eye. Graefes Arch Clin Exp Ophthalmol. 2006;244(1):109–112. doi:10.1007/s00417-005-0028-1
  • Lekhanont K, Chuckpaiwong V, Vongthongsri A, Sangiampornpanit T. Effects of sodium hyaluronate on wavefront aberrations in dry eye patients. Optom Vis Sci. 2014;91(1):39–46. doi:10.1097/OPX.0000000000000101

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.